72 Results

People

  1. Motzer
    Motzer
  2. Russo
    Russo
  3. Patil
    Patil
  4. Voss
    Voss
  5. Ginsberg
    Ginsberg
  6. Hakimi
    Hakimi
  7. Hsieh
    Hsieh
  8. Molina
    Molina
  9. Coleman
    Coleman
  10. Dinatale
    Dinatale

Groups

  1. Department of Medicine (47)
  2. Solid Tumor Oncology Division (46)
  3. Genitourinary Oncology Service (43)
  4. Surgery (12)
  5. Radiology, Department of (11)
  6. Urology (11)
  7. Body Imaging Service (9)
  8. Epidemiology and Biostatistics (8)
  9. Biostatistics Service (7)
  10. Sloan Kettering Institute Postdocs (6)
  1. "kidney metastasis"
Formats
  1. Journal Article (65)
  2. Review (3)
  3. Editorial (2)
  4. Correspondence (1)
  5. Research Letter (1)
Groups
  1. Department of Medicine (47)
  2. Solid Tumor Oncology Division (46)
  3. Genitourinary Oncology Service (43)
  4. Surgery (12)
  5. Radiology, Department of (11)
  6. Urology (11)

More Groups

People
  1. Robert Motzer (38)
  2. Paul Russo (9)
  3. Martin Voss (5)
  4. Sujata Patil (5)
  5. Abraham Hakimi (4)
  6. Ana Maria Molina (4)

More People

Years
  1. 2025 (1)
  2. 2024 (1)
  3. 2023 (3)
  4. 2022 (3)
  5. 2021 (5)
  6. 2020 (9)

More Years

Publications
  1. European Journal of Cancer (6)
  2. British Journal of Cancer (5)
  3. European Urology (5)
  4. Urology (5)
  5. Clinical Genitourinary Cancer (4)
  6. Annals of Oncology (3)

More Publications

Publishers
  1. Elsevier Science, Inc. (16)
  2. Elsevier Inc. (15)
  3. Nature Publishing Group (7)
  4. Wiley Blackwell (7)
  5. American Association for Cancer Research (4)
  6. Oxford University Press (4)

More Publishers

Results (72)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Atezolizumab plus bevacizumab versus sunitinib for patients with untreated metastatic renal cell carcinoma and sarcomatoid features: A prespecified subgroup analysis of the IMmotion151 clinical trial
    Journal Article

    Rini, B. I.; Motzer, R. J.; Powles, T.; McDermott, D. F.; Escudier, B.; Donskov, F.; Hawkins, R.; Bracarda, S.; Bedke, J.; De Giorgi, U.; more...
    European Urology (2021)

    Fulltext@MSK | Save
  • Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes
    Journal Article

    Laccetti, A. L.; Garmezy, B.; Xiao, L.; Economides, M.; Venkatesan, A.; Gao, J.; Jonasch, E.; Corn, P.; Zurita-Saavedra, A.; Brown, L. C.; more...
    Cancer Medicine (2021)

    Fulltext@MSK | Save
  • Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma
    Journal Article

    Lee, C. H.; Motzer, R. J.; Glen, H.; Michaelson, M. D.; Larkin, J.; Minoshima, Y.; Kanekiyo, M.; Ikezawa, H.; Sachdev, P.; Dutcus, C. E.; more...
    British Journal of Cancer (2021)

    Fulltext@MSK | Save
  • The importance of multidisciplinary care for spine metastases: Initial tumor management
    Review

    Newman, W. C.; Patel, A.; Goldberg, J. L.; Bilsky, M. H.
    Neuro-Oncology Practice (2020)

    Fulltext@MSK | Save
  • Preoperative nomogram predicting 12-year probability of metastatic renal cancer – Evaluation in a contemporary cohort
    Journal Article

    Mano, R.; Duzgol, C.; Ganat, M.; Goldman, D. A.; Blum, K. A.; Silagy, A. W.; Walasek, A.; Sanchez, A.; DiNatale, R. G.; Marcon, J.; more...
    Urologic Oncology: Seminars and Original Investigations (2020)

    Fulltext@MSK | Save
  • Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma
    Journal Article

    Pal, S. K.; McDermott, D. F.; Atkins, M. B.; Escudier, B.; Rini, B. I.; Motzer, R. J.; Fong, L.; Joseph, R. W.; Oudard, S.; Ravaud, A.; more...
    BJU International (2020)

    Fulltext@MSK | Save
  • Re: Brian I. Rini, Thomas Powles, Michael B. Atkins, et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): A multicentre, open-label, phase 3, randomised controlled trial. Lancet 2019;393:2404–15: Putting IMmotion into motion: Personalizing frontline treatment for metastatic renal cell carcinoma
    Correspondence

    Singla, N.
    European Urology (2020)

    Fulltext@MSK | Save
  • High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade
    Research Letter

    Yuen, K. C.; Liu, L. F.; Gupta, V.; Madireddi, S.; Keerthivasan, S.; Li, C.; Rishipathak, D.; Williams, P.; Kadel, E. E. 3rd; Koeppen, H.; more...
    Nature Medicine (2020)

    Fulltext@MSK | Save
  • Renal toxicity of systemic therapy for renal cell carcinoma
    Review

    Jaimes, E. A.
    Seminars in Nephrology (2020)

    Fulltext@MSK | Save
  • Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101
    Journal Article

    Uemura, M.; Tomita, Y.; Miyake, H.; Hatakeyama, S.; Kanayama, H. O.; Numakura, K.; Takagi, T.; Kato, T.; Eto, M.; Obara, W.; more...
    Cancer Science (2020)

    Fulltext@MSK | Save